Chimerix (NASDAQ:CMRX) was downgraded by Zacks Investment Research from a "hold" rating to a "sell" rating in a research note issued on Wednesday, Zacks.com reports.
According to Zacks, "Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. "
CMRX has been the topic of a number of other reports. BidaskClub cut shares of Chimerix from a "buy" rating to a "hold" rating in a research note on Wednesday, December 30th. HC Wainwright boosted their price target on shares of Chimerix from $7.00 to $16.00 and gave the company a "buy" rating in a research report on Monday. They noted that the move was a valuation call. Finally, Jonestrading reissued a "buy" rating and issued a $10.00 price target on shares of Chimerix in a research report on Friday, January 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company's stock. The stock presently has an average rating of "Hold" and an average price target of $9.75.
CMRX traded up $0.03 during midday trading on Wednesday, reaching $8.24. The company had a trading volume of 575,377 shares, compared to its average volume of 3,465,753. The stock has a market cap of $516.10 million, a PE ratio of -14.46 and a beta of 1.88. Chimerix has a 12-month low of $1.19 and a 12-month high of $9.66. The business has a 50-day moving average price of $5.00 and a two-hundred day moving average price of $3.47.
Chimerix (NASDAQ:CMRX) last released its earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.17) by ($0.01). The company had revenue of $1.61 million during the quarter, compared to analysts' expectations of $1.40 million. Chimerix had a negative net margin of 321.31% and a negative return on equity of 36.57%. Analysts anticipate that Chimerix will post -0.71 EPS for the current year.
Institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC acquired a new position in Chimerix during the 3rd quarter worth approximately $479,000. Boothbay Fund Management LLC acquired a new stake in shares of Chimerix during the third quarter worth approximately $378,000. Morgan Stanley grew its position in shares of Chimerix by 37.8% during the third quarter. Morgan Stanley now owns 60,487 shares of the biopharmaceutical company's stock worth $151,000 after buying an additional 16,607 shares in the last quarter. AJO LP acquired a new stake in shares of Chimerix during the third quarter worth approximately $57,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Chimerix during the third quarter worth approximately $343,000. 45.41% of the stock is currently owned by institutional investors and hedge funds.
Chimerix, Inc, a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include dociparstat sodium (DSTAT), a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of key proteins implicated in the retention and viability of acute myeloid leukemia blasts and leukemic stem cells in the bone marrow during chemotherapy; and brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox.
Featured Story: Reverse Stock Split
Get a free copy of the Zacks research report on Chimerix (CMRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Clean Energy Stocks With A Bright Future
The debate over renewable energy (i.e., clean energy) versus nonrenewable energy derived from fossil fuels was always going to come down to dollars and cents. Since 2016, things haven’t been easy for renewable energy companies. As the United States pushed towards energy independence, the Trump administration imposed tariffs on the industrial segments. The sector was subject to less favorable policies by electricity regulators. Plus, competing energy sources like coal received more help.
But a funny thing happened over the past four years. Renewable energy companies continued to grow. This is continuing a pattern that renewable sources of energy are becoming cost-competitive for businesses. And that is increasing demand.
One of the best parts of this sector for investors is that there are many ways to play the sector. In addition to solar and wind, hydrogen stocks are becoming an intriguing way to invest in renewable energy.
So rather than looking at this election as a choice between bad and good, investors should really be viewing it as a case of “good or better.” Because no matter who wins the election, clean energy stocks will continue to grow.
View the "7 Clean Energy Stocks With A Bright Future".